REGISTERED NUMBER: SC738216 (Scotland)

Unaudited Financial Statements

for the Year Ended 31 July 2026

for

Cerefuze Medical UK Ltd

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

4

DIRECTORS:

M Brassil

B Haddigan

SECRETARY:

B Haddigan

REGISTERED OFFICE:

Dept 849

1st Floor 211 Dumbarton Road

Mansfield Park

Glasgow

Scotland

G11 6AA

REGISTERED NUMBER:

SC738216 (Scotland)

ACCOUNTANTS:

Connolly Accountants & Business Advisors Ltd

Chartered Certified Accountants

The Stable Yard

25-33 Vicarage Road

Stony Stratford

Milton Keynes

Buckinghamshire

MK11 1BN

FIXED ASSETS

Tangible assets

4

3,795

6,893

CURRENT ASSETS

Debtors

5

26,474

1,841

Cash at bank

10,001

23,631

36,475

25,472

CREDITORS

Amounts falling due within one year

6

90,570

264,942

NET CURRENT LIABILITIES

(54,095

)

(239,470

)

TOTAL ASSETS LESS CURRENT LIABILITIES

(50,300

)

(232,577

)

CREDITORS

Amounts falling due after more than one year

7

84,007

-

NET LIABILITIES

(134,307

)

(232,577

)

CAPITAL AND RESERVES

Called up share capital

100

100

Retained earnings

(134,407

)

(232,677

)

SHAREHOLDERS' FUNDS

(134,307

)

(232,577

)

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 July 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 July 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 18 September 2026 and were signed on its behalf by:

B Haddigan - Director

1.	STATUTORY INFORMATION

Cerefuze Medical UK Ltd is a private company, limited by shares , registered in Scotland. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern

The financial statements have been prepared on a going concern basis. The director has confirmed that they will continue to provide financial support to the company for the foreseeable future and has no intention to withdraw this support. In light of this, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for at least 12 months from the date of approval of these financial statements.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant & machinery

-

25% on cost

Computer equipment

-

3 years

Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

Financial instruments

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provision of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic Financial Assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised costs using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is a contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors and loans from related companies are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised costs, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Research and development

Expenditure on research and development is written off in the year in which it is incurred.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 4 (2025 - 1 ) .

4.	TANGIBLE FIXED ASSETS

Plant &

Computer

machinery

equipment

Totals

£

£

£

COST

At 1 August 2025

and 31 July 2026

10,855

1,166

12,021

DEPRECIATION

At 1 August 2025

4,743

385

5,128

Charge for year

2,714

384

3,098

At 31 July 2026

7,457

769

8,226

NET BOOK VALUE

At 31 July 2026

3,398

397

3,795

At 31 July 2025

6,112

781

6,893

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2026

2025

£

£

Amounts owed by group undertakings

779

-

Other debtors

25,695

1,841

26,474

1,841

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2026

2025

£

£

Trade creditors

91

32

Amounts owed to group undertakings

-

258,548

Taxation and social security

3,821

3,649

Other creditors

86,658

2,713

90,570

264,942

7.

CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

2026

2025

£

£

Other creditors

84,007

-

8.	RELATED PARTY DISCLOSURES

As at 31 July 2026 Cerefuze Medical UK Ltd owed £Nil (2025 - £258,548) to Smart Reactors Service Ltd, an Irish company which is related to the directors.

As at 31 July 2026 Cerefuze Medical UK Ltd was owed £779 (2025 - £Nil) to Smart Reactors UK Ltd, a company which is related to the directors.